Thiazolidinediones (TZDs), synthetic agonists of PPARγ, are widely used in clinic for improving hepatic injury in NAFLD patients [11, 19–21]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.